Size Effect on Lipid Nanocapsule-Mediated GLP-1 Secretion from Enteroendocrine L Cells
- 15 December 2017
- journal article
- research article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 15 (1) , 108-115
Abstract
L cells are enteroendocrine cells located throughout the gastrointestinal tract that secrete physiologically important peptides. The most characterized peptides secreted by L cells are the peptide YY (PYY) and the glucagon-like peptide (GLP) -1 and -2. These peptides are released rapidly into the circulation after oral nutrient ingestion. Recently, lipid-based nanoparticles (NP) have been described as triggers for GLP-1 secretion by L cells. NP physicochemical properties play a key role in the NP-cell interaction, and drive NP cell internalization. We herein hypothesize that lipid-based NP with appropriate size would not only be able to deliver drugs into blood circulation, but also act like endogenous ligands to stimulate GLP-1 secretion. We tested five different size (25, 50, 100, 150 and 200 nm) lipid nanocapsules (LNC) on murine L cells in vitro to confirm this hypothesis. Our study showed that GLP-1 secretion was induced only by the 200 nm size LNC, highlighting the importance of LNC particle size on the secretion of GLP-1 by L cells. The different formulations did not affect proglucagon mRNA expression, suggesting there was not an increased GLP-1 synthesis. As a proof of concept, we further demonstrated in normoglycemic mice that 200 nm LNC administration increases GLP-1 levels by 4- and 3-fold compared to untreated control mice 60 and 180 min after the administration, respectively. Our study suggests that 200 nm LNC as a nanocarrier to encapsulate drug candidates and as a ligand to induce endogenous GLP-1 secretion might represent a promising strategy for type 2 diabetes mellitus treatment.Keywords
Funding Information
- Fonds De La Recherche Scientifique - FNRS (WELBIO-CGR-2017)
- China Scholarship Council
- FP7 Ideas: European Research Council (336452)
- Artois-Baillet Latour Foundation
This publication has 45 references indexed in Scilit:
- Oral hypoglycaemic effect of GLP-1 and DPP4 inhibitor based nanocomposites in a diabetic animal modelJournal of Controlled Release, 2016
- The impact of nanoparticles on the mucosal translocation and transport of GLP-1 across the intestinal epitheliumBiomaterials, 2014
- Nutrient detection by incretin hormone secreting cellsPhysiology & Behavior, 2012
- Targeting GPR120 and other fatty acid-sensing GPCRs ameliorates insulin resistance and inflammatory diseasesTrends in Pharmacological Sciences, 2011
- A Gut Feeling for Obesity: 7TM Sensors on Enteroendocrine CellsCell Metabolism, 2008
- Glucose Sensing in L Cells: A Primary Cell StudyCell Metabolism, 2008
- Biology of Incretins: GLP-1 and GIPGastroenterology, 2007
- The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetesThe Lancet, 2006
- Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIPAmerican Journal of Physiology-Endocrinology and Metabolism, 2006
- Cloning of adiponectin receptors that mediate antidiabetic metabolic effectsNature, 2003